On July 21, 2025, DSS, Inc. entered into a Debt Conversion Agreement with Impact Biomedical Inc. to settle $12 million of debt in exchange for 31,939,778 shares of Impact's common stock, resolving all outstanding obligations. This agreement finalizes the debt terms previously amended on January 18, 2024.